MINNEAPOLIS--(BUSINESS WIRE)--Dec. 21, 2005--MGI PHARMA, INC. (Nasdaq:MOGN), an oncology and acute care focused biopharmaceutical company, today announced top line results from a randomized, double-blind, multi-center phase 2 dose ranging study of Aquavan(R) (fospropofol disodium) Injection in patients undergoing colonoscopy. In addition, the Company provided an overview of the pivotal program that is intended to serve as a basis for registration of Aquavan Injection for use as a sedative in patients undergoing procedures requiring minimal to moderate sedation. This pivotal program is planned to begin in early 2006.